U.S. veterans dept to limit diabetes drug Avandia
Key points
- Department of Veterans Affairs has decided to "severely limit" the use of the diabetes drug Avandia over safety concerns, the New York Times reported on Wednesday.
- The agency, which treated more than 5 million military veterans last year, removed the drug from its "formulary," or list of approved drugs, on October 5 the paper said.
- VA sales make up about 8 percent the sales of Avandia, know generically as rosiglitazone maleate, the paper said.
- Once a $2.2 billion franchise for the British drugmaker GlaxoSmithKline Plc, U.S.
The U.S. Department of Veterans Affairs has decided to "severely limit" the use of the diabetes drug Avandia over safety concerns, the New York Times reported on Wednesday.
The agency, which treated more than 5 million military veterans last year, removed the drug from its "formulary," or list of approved drugs, on October 5 the paper said. It will allow patients currently taking the drug to continue although it is urging doctors to inform patients about the risks.
VA sales make up about 8 percent the sales of Avandia, know generically as rosiglitazone maleate, the paper said.
Once a $2.2 billion franchise for the British drugmaker GlaxoSmithKline Plc, U.S. Avandia sales have fallen an estimated 60 percent since May since The New England Journal of Medicine published an analysis questioning the drug's safety, the Times said.
The article suggested that using the drug increased the risk of a heart attack by more than 40 percent. The Food and Drug Administration is reviewing the drug, it said.
A Glaxo spokeswoman said it was too early to say what the impact of the VA decision will have on the drug and said it did not believe the decision was in the best interest of patients, according to the paper.
The VA issued more than 161,000 Avandia prescriptions from September 2006 to August 2007, the paper said.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Diabetes & Hormones →
NewsPeople at risk of diabetes offer clues toward novel drugs
Once people develop type 2 diabetes, high blood glucose levels alter their metabolism so much that it becomes difficult to sift through all the clues to find what might enable the disease. "To identify factors that play…
15 February 2011
NewsDepomed recalls 52 lots of diabetes drug
Drug developer Depomed Inc (DEPO.O) said it will recall 52 lots of its diabetes drug Glumetza due to the presence of traces of a certain chemical in the tablet's 500 mg bottle. The recall followed an investigation of a…
18 June 2010
NewsCommon diabetes drug linked to vitamin deficiency
Patients treated over long periods with metformin, a common drug for diabetes, are at risk of developing vitamin B12 deficiency which is also likely to get worse over time, according to a study published on Friday.…
22 May 2010
